CHD1L — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL20353975	0.78	1/20
SCHEMBL681883	0.76	1/20
SCHEMBL21571475	0.67	1/20
SCHEMBL21603922	0.64	1/20
SCHEMBL24426884	0.63	1/20
SCHEMBL20339087	0.62	1/20
SCHEMBL21571479	0.62	1/20
SCHEMBL15281318	0.60	1/20
SCHEMBL3917747	0.60	1/20
SCHEMBL20340280	0.57	1/20
SCHEMBL29403396	0.57	1/20
SCHEMBL24426885	0.56	1/20
SCHEMBL24426732	0.55	1/20
SCHEMBL20340699	0.54	1/20
SCHEMBL20353929	0.54	1/20
SCHEMBL20353834	0.54	1/20
SCHEMBL20354010	0.52	1/20
SCHEMBL20339092	0.51	1/20
SCHEMBL20340345	0.51	1/20
SCHEMBL20344333	0.50	1/20

Clinical trials — most relevant to CHD1L by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment	PHASE2/PHASE3	RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Vorinostat in Children	PHASE1/PHASE2	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors	PHASE1	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Changes Associated With H. Pylori and Gastric Carcinogenesis	nan	ACTIVE_NOT_RECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins	nan	COMPLETED
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy	nan	NOT_YET_RECRUITING
Clinical and Molecular Study of CHARGE Syndrom	nan	COMPLETED
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve	nan	UNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Precision High-Intensity Training Through Epigenetics (PHITE)	nan	COMPLETED
Genetic of SportS Induced Endofibrotic Remodeling	nan	COMPLETED
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome	nan	COMPLETED
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
UTHealth Turner Syndrome Research Registry	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CHD1L binder may also engage these)

Protein	Name	Similarity
Q9CXF7	—	1.000	Q9CXF7 →
Q3B7N1	—	1.000	Q3B7N1 →
Q7ZU90	—	0.996	Q7ZU90 →
RAD54L	DNA repair and recombination protein RAD54-like	0.987	landscape →
POLQ	DNA polymerase theta	0.987	landscape →
D3ZA12	—	0.986	D3ZA12 →
Q6PCN7	—	0.985	Q6PCN7 →
P40694	—	0.985	P40694 →
A3KFM7	—	0.984	A3KFM7 →
B6ZLK2	—	0.984	B6ZLK2 →
Q5RF63	—	0.984	Q5RF63 →
Q9Z129	—	0.984	Q9Z129 →
Q95216	—	0.984	Q95216 →
Q9NY93	—	0.983	Q9NY93 →
RECQL	ATP-dependent DNA helicase Q1	0.983	landscape →
Q6AYJ1	—	0.983	Q6AYJ1 →
O12944	—	0.983	O12944 →
Q96BT7	—	0.983	Q96BT7 →
Q14527	—	0.983	Q14527 →
Q8TD26	—	0.983	Q8TD26 →
E9PZM4	—	0.983	E9PZM4 →
Q9Y4B4	—	0.983	Q9Y4B4 →
Q6NZQ2	—	0.982	Q6NZQ2 →
Q95K79	—	0.982	Q95K79 →
P70270	—	0.982	P70270 →
Q9ESV0	—	0.982	Q9ESV0 →
O09053	—	0.982	O09053 →
Q60560	—	0.982	Q60560 →
Q8BJL0	—	0.982	Q8BJL0 →
P40201	—	0.981	P40201 →